{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:37:11Z","timestamp":1793655431513,"version":"4.5.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-025-01139-1","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:41:46Z","timestamp":1761864106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Establishing the Human Duodenum Chip as a Surrogate for Effective Human Permeability: In Vitro and In Silico Assessment"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4691-7853","authenticated-orcid":false,"given":"Kellyn M. Patros","family":"Zagaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-9876","authenticated-orcid":false,"given":"Anna K.","family":"Kopec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9168-3325","authenticated-orcid":false,"given":"Julie","family":"Harney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9285-444X","authenticated-orcid":false,"given":"Mark A.","family":"Hardink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4229-9843","authenticated-orcid":false,"given":"Bart","family":"Hens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"1139_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ejps.2011.12.007","volume":"45","author":"ST Buckley","year":"2012","unstructured":"Buckley ST, Fischer SM, Fricker G, Brandl M. In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives. Eur J Pharm Sci. 2012;45:235\u201350.","journal-title":"Eur J Pharm Sci"},{"key":"1139_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.xphs.2020.07.001","volume":"110","author":"S Youhanna","year":"2021","unstructured":"Youhanna S, Lauschke VM. The past, present and future of intestinal in vitro cell systems for drug absorption studies. J Pharm Sci. 2021;110:50\u201365.","journal-title":"J Pharm Sci"},{"key":"1139_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s44222-023-00130-9","volume":"2","author":"YC Shin","year":"2024","unstructured":"Shin YC, Than N, Min S, Shin W, Kim HJ. Modelling host\u2013microbiome interactions in organ-on-a-chip platforms. Nat Rev Bioeng. 2024;2:175\u201391.","journal-title":"Nat Rev Bioeng"},{"key":"1139_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11080411","volume":"11","author":"D Dahlgren","year":"2019","unstructured":"Dahlgren D, Lennern\u00e4s H. Intestinal permeability and drug absorption: predictive experimental, computational and in vivo approaches. Pharmaceutics. 2019;11:411.","journal-title":"Pharmaceutics"},{"key":"1139_CR5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0016-5085(89)80072-1","volume":"96","author":"IJ Hidalgo","year":"1989","unstructured":"Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology. 1989;96:736\u201349.","journal-title":"Gastroenterology"},{"key":"1139_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0169-409X(00)00128-9","volume":"46","author":"P Artursson","year":"2001","unstructured":"Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev. 2001;46:27\u201343.","journal-title":"Adv Drug Deliv Rev"},{"key":"1139_CR7","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.1002\/jps.22674","volume":"100","author":"L Di","year":"2011","unstructured":"Di L, Whitney-Pickett C, Umland JP, Zhang H, Zhang X, Gebhard DF, et al. Development of a new permeability assay using low-efflux MDCKII cells. J Pharm Sci. 2011;100:4974\u201385.","journal-title":"J Pharm Sci"},{"key":"1139_CR8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.tcb.2011.09.005","volume":"21","author":"D Huh","year":"2011","unstructured":"Huh D, Hamilton GA, Ingber DE. From 3d cell culture to organs-on-chips. Trends Cell Biol. 2011;21:745\u201354.","journal-title":"Trends Cell Biol"},{"key":"1139_CR9","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/nprot.2013.137","volume":"8","author":"D Huh","year":"2013","unstructured":"Huh D, Kim HJ, Fraser JP, Shea DE, Khan M, Bahinski A, et al. Microfabrication of human organs-on-chips. Nat Protoc. 2013;8:2135\u201357.","journal-title":"Nat Protoc"},{"key":"1139_CR10","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.50135","volume":"9","author":"M Kasendra","year":"2020","unstructured":"Kasendra M, Luc R, Yin J, Manatakis DV, Kulkarni G, Lucchesi C, et al. Duodenum intestine-chip for preclinical drug assessment in a human relevant model. Elife. 2020;9:e50135.","journal-title":"Elife"},{"key":"1139_CR11","doi-asserted-by":"publisher","first-page":"C151","DOI":"10.1152\/ajpcell.00120.2020","volume":"319","author":"C Corr\u00f2","year":"2020","unstructured":"Corr\u00f2 C, Novellasdemunt L, Li VSW. A brief history of organoids. Am J Physiol-Cell Physiol. 2020;319:C151\u201365.","journal-title":"Am J Physiol-Cell Physiol"},{"key":"1139_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122875","volume":"352","author":"IA Parente","year":"2024","unstructured":"Parente IA, Chiara L, Bertoni S. Exploring the potential of human intestinal organoids: applications, challenges, and future directions. Life Sci. 2024;352:122875.","journal-title":"Life Sci"},{"key":"1139_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nature07935","volume":"459","author":"T Sato","year":"2009","unstructured":"Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262\u20135.","journal-title":"Nature"},{"key":"1139_CR14","doi-asserted-by":"crossref","unstructured":"Kassis J, Wan Z. Editorial: Latest advancements in organ-on-a-chip technology. Front Pharmacol. 2025. https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2025.1631320\/full","DOI":"10.3389\/fphar.2025.1631320"},{"key":"1139_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106481","volume":"188","author":"S Kourula","year":"2023","unstructured":"Kourula S, Derksen M, Jardi F, Jonkers S, van Heerden M, Verboven P, et al. Intestinal organoids as an in vitro platform to characterize disposition, metabolism, and safety profile of small molecules. Eur J Pharm Sci. 2023;188:106481.","journal-title":"Eur J Pharm Sci"},{"key":"1139_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2019.101383","volume":"35","author":"M Bardenbacher","year":"2019","unstructured":"Bardenbacher M, Ruder B, Britzen-Laurent N, Schmid B, Waldner M, Naschberger E, et al. Permeability analyses and three dimensional imaging of interferon gamma-induced barrier disintegration in intestinal organoids. Stem Cell Res. 2019;35:101383.","journal-title":"Stem Cell Res"},{"key":"1139_CR17","first-page":"361","volume":"17","author":"P Bransford","year":"2020","unstructured":"Bransford P, Cook J, Gupta M, Haertter S, He H, Ju R, et al. ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ Consortium. Mol Pharm. 2020;17:361\u201372.","journal-title":"Mol Pharm"},{"key":"1139_CR18","unstructured":"Emulate. Duodenum Intestine-Chip Culture Protocol. Emulate.\u00a0https:\/\/emulatebio.com\/support\/ep203-rev-a\/"},{"key":"1139_CR19","doi-asserted-by":"crossref","unstructured":"Shin W, Ambrosini YM, Shin YC, Wu A, Min S, Koh D, et al. Robust Formation of an Epithelial Layer of Human Intestinal Organoids in a Polydimethylsiloxane-Based Gut-on-a-Chip Microdevice. Front Med Technol. 2020. https:\/\/www.frontiersin.org\/journals\/medical-technology\/articles\/10.3389\/fmedt.2020.00002\/full","DOI":"10.3389\/fmedt.2020.00002"},{"key":"1139_CR20","doi-asserted-by":"publisher","first-page":"14012","DOI":"10.1038\/s41598-025-97111-2","volume":"15","author":"K Grindulis","year":"2025","unstructured":"Grindulis K, Matusevica NG, Kozlova V, Rimsa R, Klavins K, Mozolevskis G. Sorption and release of small molecules in PDMS and COC for organs on chip. Sci Rep. 2025;15:14012.","journal-title":"Sci Rep"},{"key":"1139_CR21","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1208\/s12248-014-9616-5","volume":"16","author":"R Li","year":"2014","unstructured":"Li R, Bi Y-A, Lai Y, Sugano K, Steyn SJ, Trapa PE, et al. Permeability comparison between hepatocyte and low efflux MDCKII cell monolayer. AAPS J. 2014;16:802\u20139.","journal-title":"AAPS J"},{"key":"1139_CR22","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1021\/acs.molpharmaceut.6b00724","volume":"14","author":"GH Goetz","year":"2017","unstructured":"Goetz GH, Shalaeva M, Caron G, Ermondi G, Philippe L. Relationship between passive permeability and molecular polarity using block relevance analysis. Mol Pharm. 2017;14:386\u201393.","journal-title":"Mol Pharm"},{"issue":"2","key":"1139_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2125.2011.03961.x","volume":"72","author":"E Callegari","year":"2011","unstructured":"Callegari E, Malhotra B, Bungay PJ, Webster R, Fenner KS, Kempshall S, et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011;72(2):235\u201346.","journal-title":"Br J Clin Pharmacol"},{"key":"1139_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1208\/s12248-009-9107-2","volume":"11","author":"V Lukacova","year":"2009","unstructured":"Lukacova V, Woltosz WS, Bolger MB. Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data. AAPS J. 2009;11:323\u201334.","journal-title":"AAPS J"},{"key":"1139_CR25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1023\/A:1011988601696","volume":"15","author":"ND Eddington","year":"1998","unstructured":"Eddington ND, Marroum P, Uppoor R, Hussain A, Augsburger L. Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation. Pharm Res. 1998;15:466\u201373.","journal-title":"Pharm Res"},{"key":"1139_CR26","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1021\/mp500210c","volume":"11","author":"DM Mudie","year":"2014","unstructured":"Mudie DM, Murray K, Hoad CL, Pritchard SE, Garnett MC, Amidon GL, et al. Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state. Mol Pharm. 2014;11:3039\u201347.","journal-title":"Mol Pharm"},{"key":"1139_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3390\/pharmaceutics11050215","volume":"11","author":"MD Duque","year":"2019","unstructured":"Duque MD, Silva DA, Issa MG, Porta V, L\u00f6benberg R, Ferraz HG. In silico prediction of plasma concentrations of fluconazole capsules with different dissolution profiles and bioequivalence study using population simulation. Pharmaceutics. 2019;11:215.","journal-title":"Pharmaceutics"},{"key":"1139_CR28","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/bcp.14492","volume":"87","author":"F Xie","year":"2021","unstructured":"Xie F, Van Bocxlaer J, Vermeulen A. Physiologically based pharmacokinetic modelling of lisinopril in children: a case story of angiotensin converting enzyme inhibitors. Br J Clin Pharmacol. 2021;87:1203\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"1139_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejps.2014.11.010","volume":"67","author":"B Wuyts","year":"2015","unstructured":"Wuyts B, Riethorst D, Brouwers J, Tack J, Annaert P, Augustijns P. Evaluation of fasted state human intestinal fluid as apical solvent system in the Caco-2 absorption model and comparison with FaSSIF. Eur J Pharm Sci. 2015;67:126\u201335.","journal-title":"Eur J Pharm Sci"},{"key":"1139_CR30","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/00498250701704819","volume":"37","author":"H Lennern\u00e4s","year":"2007","unstructured":"Lennern\u00e4s H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica. 2007;37:1015\u201351.","journal-title":"Xenobiotica"},{"key":"1139_CR31","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1016\/j.xphs.2016.01.027","volume":"105","author":"R Cristofoletti","year":"2016","unstructured":"Cristofoletti R, Charoo NA, Dressman JB. Exploratory investigation of the limiting steps of oral absorption of Fluconazole and Ketoconazole in children using an in silico pediatric absorption model. J Pharm Sci. 2016;105:2794\u2013803.","journal-title":"J Pharm Sci"},{"issue":"6","key":"1139_CR32","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1021\/mp500834v","volume":"12","author":"E Sj\u00f6gren","year":"2015","unstructured":"Sj\u00f6gren E, Dahlgren D, Roos C, Lennern\u00e4s H. Human in vivo regional intestinal permeability: quantitation using site-specific drug absorption data. Mol Pharm. 2015;12(6):2026\u201339.","journal-title":"Mol Pharm"},{"key":"1139_CR33","first-page":"103","volume":"6","author":"J Song","year":"2025","unstructured":"Song J, Zhao T. Deformable and degradable nanozymes for inhaled viral pneumonia treatment. Biomater Transl. 2025;6:103\u20135.","journal-title":"Biomater Transl"},{"key":"1139_CR34","first-page":"106","volume":"6","author":"H Du","year":"2025","unstructured":"Du H, Liu J, Zhang M. Peptide-assembled nanozymes: a promising strategy to combat antimicrobial resistance. Biomater Transl. 2025;6:106\u20139.","journal-title":"Biomater Transl"},{"issue":"2","key":"1139_CR35","doi-asserted-by":"publisher","DOI":"10.36922\/OR025210018","volume":"1","author":"RL Reis","year":"2025","unstructured":"Reis RL. Materiobiology-driven engineering for next-generation organoids. Organoid Research. 2025;1(2):025210018.","journal-title":"Organoid Research"},{"issue":"2","key":"1139_CR36","doi-asserted-by":"publisher","DOI":"10.36922\/OR025110011","volume":"1","author":"L Guo","year":"2025","unstructured":"Guo L, Xia Y, Pan P, Chen J. Bone marrow organoids: decoding the three-dimensional code of hematopoietic niches. Organoid Research. 2025;1(2):025110011.","journal-title":"Organoid Research"},{"key":"1139_CR37","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/aor.14503","volume":"47","author":"JJ Han","year":"2023","unstructured":"Han JJ. FDA modernization act 2.0 allows for alternatives to animal testing. Artif Organs. 2023;47:449\u201350.","journal-title":"Artif Organs"},{"key":"1139_CR38","unstructured":"US Food & Drug Administration. FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs. FDA. FDA; 2025.\u00a0\u00a0https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01139-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01139-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01139-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:20:48Z","timestamp":1770826848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01139-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1139"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01139-1","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. KPZ, AK, JH, MH, JM & BH are employees of Pfizer Inc. and may own Pfizer stock.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"9"}}